New blood filter could ease heart drug dependence in shock patients

NCT ID NCT05027529

Completed Disease control Sponsor: Christian Schulze Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding a special blood filter called CytoSorb to standard ECMO support helps people with cardiogenic shock (a severe form of heart failure). The filter aims to remove inflammatory substances from the blood. Researchers measured how much heart-support medication patients needed after 72 hours. The trial included 42 critically ill adults and compared those getting ECMO plus the filter to those getting ECMO alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CytoSorb device (a filter that removes inflammatory substances from the blood)
What this could lead to: If it works, this could point toward a way to reduce the need for strong heart medications in patients on ECMO for cardiogenic shock.
What could go wrong: This is a small, early-stage trial with only 42 patients, so results may not apply broadly. The device adds complexity and may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOGENIC SHOCK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiogenic shock multiple organ dysfunction syndrome Shock, Cardiogenic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOGENIC SHOCK

Contacts and locations

Locations

Jena University Hospital, Department of Cardiology

Jena, Thuringia, 07747, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.